Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03526250
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:04.258369+00:00
Published At
2024-04-24T00:00:00+00:00
Record Updated At
2026-04-03
Results Posted At
2024-04-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Malignant Solid Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Kidney Wilms Tumor", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-03"
protocolSection.identificationModule.nctId
"NCT03526250"
protocolSection.identificationModule.officialTitle
"NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2024-04-24"

Study condition terms

  • Advanced Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Ependymoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ewing Sarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Glioma (protocolSection.conditionsModule.conditions)
  • Recurrent Hepatoblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Kidney Wilms Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Langerhans Cell Histiocytosis (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Germ Cell Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Glioma (protocolSection.conditionsModule.conditions)
  • Recurrent Medulloblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Osteosarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Peripheral Primitive Neuroectodermal Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Rhabdomyosarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Soft Tissue Sarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Ependymoma (protocolSection.conditionsModule.conditions)
  • Refractory Ewing Sarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Glioma (protocolSection.conditionsModule.conditions)
  • Refractory Hepatoblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Langerhans Cell Histiocytosis (protocolSection.conditionsModule.conditions)
  • Refractory Malignant Germ Cell Tumor (protocolSection.conditionsModule.conditions)
  • Refractory Malignant Glioma (protocolSection.conditionsModule.conditions)
  • Refractory Medulloblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Osteosarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Peripheral Primitive Neuroectodermal Tumor (protocolSection.conditionsModule.conditions)
  • Refractory Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Refractory Rhabdomyosarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Soft Tissue Sarcoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.